Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey

Social acceptability of psilocybin-assisted therapy for existential distress at the end of life: A population-based survey
Palliative Medicine, by Louis Plourde, Sue-Ling Chang, Houman Farzin, Pierre Gagnon, Johanne Hébert, Robert Foxman, Pierre Deschamps, François Provost, Marianne Masse-Grenier, Jean-François Stephan, Katherine Cheung, Yann Joly, Jean-Sébastien Fallu, Michel Dorval for the P3A Study Group; 2/24
Internationally, there is a growing interest in the potential benefits of psilocybin-assisted therapy to treat existential distress at the end of life. However, the social acceptability of this therapy is not yet well known. The social acceptability of psilocybin-assisted therapy for existential distress at the end of life is rather high in Canada. These findings may contribute to efforts to mobilise resources and improve access to this emerging therapy in palliative and end of life care settings.